Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mingyuan Medicare Development Acquires Shanghai Kang Pei Bio-Medical

This article was originally published in PharmAsia News

Executive Summary

Following an agreement in October, Mingyuan Medicare Development has completed the acquisition of 75 percent stake in Shanghai Kang Pei Bio-Medical with RMB 310 million in cash. Together with three subsidiaries and two joint-venture firms, Kang Pei Bio-Medical focuses on providing medical diagnosis, check-ups and health care evaluation services to China's customers, including Mingyuan Medicare's affiliated companies for the past two years. Kang Pei Bio-Medical has set up 12 health care centers in Shanghai, Tianjin, Chengdu and Taiyuan; these facilities annually service more than 400,000 customers. (Click here for more - Chinese Language)

You may also be interested in...

Bayer's Finerenone Hints Positive In Diabetic Kidney Disease

The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.

Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism

Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.

US FDA Announces Plans To Resume Domestic Inspections

Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts